{
    "organizations": [],
    "uuid": "88722ccdc77c5b11e4589600cd15fe12c6c0935c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-reg-dbv-technologies-provides-upda/brief-reg-dbv-technologies-provides-update-on-regulatory-progress-for-viaskin-peanut-idUSFWN1Q31GN",
    "ord_in_thread": 0,
    "title": "BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Dbv Technologies Sa:\n* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT\n* FDA AGREED TO SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) FOR TREATMENT OF PEANUT ALLERGY IN CHILDREN AGED 4 TO 11\n* DBV REMAINS ON TRACK TO SUBMIT ITS BLA IN SECOND HALF OF 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-14T14:36:00.000+02:00",
    "crawled": "2018-02-15T20:48:37.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "dbv",
        "technology",
        "sa",
        "technology",
        "provides",
        "update",
        "regulatory",
        "progress",
        "viaskin",
        "peanut",
        "fda",
        "agreed",
        "submission",
        "biologics",
        "license",
        "application",
        "bla",
        "treatment",
        "peanut",
        "allergy",
        "child",
        "aged",
        "dbv",
        "remains",
        "track",
        "submit",
        "bla",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}